Clinical efficacy of immune checkpoint inhibitors in the treatment of unresectable advanced or recurrent gastric cancer: An evidence-based review of therapies

Kazuhiro Togasaki, Yasutaka Sukawa, Takanori Kanai, Hiromasa Takaishi

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

Standard treatment options for patients with advanced gastric cancer (GC) offer limited efficacy and are associated with some toxicity, which necessitates the development of more effective therapies for improving the treatment outcomes for this disease. Immunotherapy involving immune checkpoint inhibitors (ICIs) which inhibit the programmed death 1 (PD-1)/ programmed death ligand 1 interaction has emerged as a new treatment option. Nivolumab, a human IgG4 monoclonal antibody inhibitor of PD-1, has demonstrated promising clinical activity and induced durable responses in patients with advanced GC. Nivolumab has recently been approved for treating patients with pretreated advanced GC in Japan. In the present review, we summarized current evidence of the clinical efficacy of ICIs in a variety of solid tumors and reported our experience in patients with GC who were treated with nivolumab and the interesting features that were observed in these cases. Certain ICI-specific clinical features such as pseudo-and hyper-progression of tumor and hyper-response to subsequent chemotherapy have been reported in several cancer types. Lastly, we discussed the present scenario regarding research on biomarkers for assessing the clinical benefits of ICI therapies.

Original languageEnglish
Pages (from-to)8239-8250
Number of pages12
JournalOncoTargets and Therapy
Volume11
DOIs
Publication statusPublished - 2018 Jan 1

Fingerprint

Stomach Neoplasms
Neoplasms
Therapeutics
Immunotherapy
Japan
Immunoglobulin G
Biomarkers
Monoclonal Antibodies
Ligands
Drug Therapy
Research
nivolumab

Keywords

  • Avelumab
  • Hyperprogression
  • Hypersensitivity
  • Microbiome
  • Nivolumab
  • Pembrolizumab
  • Pseudoprogression

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Cite this

@article{ce87ea3d5a524a1aa01eec757f981490,
title = "Clinical efficacy of immune checkpoint inhibitors in the treatment of unresectable advanced or recurrent gastric cancer: An evidence-based review of therapies",
abstract = "Standard treatment options for patients with advanced gastric cancer (GC) offer limited efficacy and are associated with some toxicity, which necessitates the development of more effective therapies for improving the treatment outcomes for this disease. Immunotherapy involving immune checkpoint inhibitors (ICIs) which inhibit the programmed death 1 (PD-1)/ programmed death ligand 1 interaction has emerged as a new treatment option. Nivolumab, a human IgG4 monoclonal antibody inhibitor of PD-1, has demonstrated promising clinical activity and induced durable responses in patients with advanced GC. Nivolumab has recently been approved for treating patients with pretreated advanced GC in Japan. In the present review, we summarized current evidence of the clinical efficacy of ICIs in a variety of solid tumors and reported our experience in patients with GC who were treated with nivolumab and the interesting features that were observed in these cases. Certain ICI-specific clinical features such as pseudo-and hyper-progression of tumor and hyper-response to subsequent chemotherapy have been reported in several cancer types. Lastly, we discussed the present scenario regarding research on biomarkers for assessing the clinical benefits of ICI therapies.",
keywords = "Avelumab, Hyperprogression, Hypersensitivity, Microbiome, Nivolumab, Pembrolizumab, Pseudoprogression",
author = "Kazuhiro Togasaki and Yasutaka Sukawa and Takanori Kanai and Hiromasa Takaishi",
year = "2018",
month = "1",
day = "1",
doi = "10.2147/OTT.S152514",
language = "English",
volume = "11",
pages = "8239--8250",
journal = "OncoTargets and Therapy",
issn = "1178-6930",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Clinical efficacy of immune checkpoint inhibitors in the treatment of unresectable advanced or recurrent gastric cancer

T2 - An evidence-based review of therapies

AU - Togasaki, Kazuhiro

AU - Sukawa, Yasutaka

AU - Kanai, Takanori

AU - Takaishi, Hiromasa

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Standard treatment options for patients with advanced gastric cancer (GC) offer limited efficacy and are associated with some toxicity, which necessitates the development of more effective therapies for improving the treatment outcomes for this disease. Immunotherapy involving immune checkpoint inhibitors (ICIs) which inhibit the programmed death 1 (PD-1)/ programmed death ligand 1 interaction has emerged as a new treatment option. Nivolumab, a human IgG4 monoclonal antibody inhibitor of PD-1, has demonstrated promising clinical activity and induced durable responses in patients with advanced GC. Nivolumab has recently been approved for treating patients with pretreated advanced GC in Japan. In the present review, we summarized current evidence of the clinical efficacy of ICIs in a variety of solid tumors and reported our experience in patients with GC who were treated with nivolumab and the interesting features that were observed in these cases. Certain ICI-specific clinical features such as pseudo-and hyper-progression of tumor and hyper-response to subsequent chemotherapy have been reported in several cancer types. Lastly, we discussed the present scenario regarding research on biomarkers for assessing the clinical benefits of ICI therapies.

AB - Standard treatment options for patients with advanced gastric cancer (GC) offer limited efficacy and are associated with some toxicity, which necessitates the development of more effective therapies for improving the treatment outcomes for this disease. Immunotherapy involving immune checkpoint inhibitors (ICIs) which inhibit the programmed death 1 (PD-1)/ programmed death ligand 1 interaction has emerged as a new treatment option. Nivolumab, a human IgG4 monoclonal antibody inhibitor of PD-1, has demonstrated promising clinical activity and induced durable responses in patients with advanced GC. Nivolumab has recently been approved for treating patients with pretreated advanced GC in Japan. In the present review, we summarized current evidence of the clinical efficacy of ICIs in a variety of solid tumors and reported our experience in patients with GC who were treated with nivolumab and the interesting features that were observed in these cases. Certain ICI-specific clinical features such as pseudo-and hyper-progression of tumor and hyper-response to subsequent chemotherapy have been reported in several cancer types. Lastly, we discussed the present scenario regarding research on biomarkers for assessing the clinical benefits of ICI therapies.

KW - Avelumab

KW - Hyperprogression

KW - Hypersensitivity

KW - Microbiome

KW - Nivolumab

KW - Pembrolizumab

KW - Pseudoprogression

UR - http://www.scopus.com/inward/record.url?scp=85057719230&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85057719230&partnerID=8YFLogxK

U2 - 10.2147/OTT.S152514

DO - 10.2147/OTT.S152514

M3 - Review article

AN - SCOPUS:85057719230

VL - 11

SP - 8239

EP - 8250

JO - OncoTargets and Therapy

JF - OncoTargets and Therapy

SN - 1178-6930

ER -